METTL14 inhibits cellular antiviral response to RNA virus. A) qPCR analysis of Ifnb1 mRNA in Mettl14
+/+ and Mettl14
+/− peritoneal macrophages infected with VSV (MOI, 0.1) for 12 h. B) qPCR analysis of VSV mRNA (left) and plaque assay of VSV titers (right) in Mettl14
+/+ and Mettl14
+/− peritoneal macrophages infected with VSV (MOI, 0.1) for 12 h. C) qPCR analysis of Ifnb1 mRNA in HEK293T cells transfected with indicated plasmids for 24 h, followed by infection with VSV (MOI, 0.1) for 12 h. D) qPCR analysis of VSV mRNA (left) and plaque assay of VSV titers (right) in HEK293T cells transfected as in (C), followed by infection with VSV (MOI, 0.1) for 12 h. E) Immunoblot analysis of VSV glycoprotein (VSV‐G) in HEK293T cells transfected as in (C), followed by infection with VSV for the indicated times. F) Fluorescence microscopy (above) and flow cytometry analysis (bottom) of VSV‐GFP replication in HEK293T cells transfected with control siRNA (siCtrl) or siRNA targeting METTL14 (siMETTL14) for 48 h, followed by infection with VSV‐GFP (MOI, 0.1) for 12 h (bright‐field, upper; fluorescence, bottom). Scale bars, 100 µm. G) Fluorescence microscopy (above) and flow cytometry analysis (bottom) of VSV‐GFP replication in HEK293T cells transfected as in (C), followed by infection with VSV‐GFP (MOI, 0.05) for 12 h (bright‐field, upper; fluorescence, bottom). Scale bars, 100 µm. Data information: Data are presented as mean ± S.D. Two‐tailed unpaired Student's t‐test; *P < 0.05; **P < 0.01 (A–D).